MIDATECH PHARMA
R&D | Overview & Pipeline

Midatech’s three innovative drug delivery platforms are designed to create improved versions of existing therapies using targeted delivery, sustained release and advanced solvation technologies.  Midatech has an internal pipeline of high potential new drug products in development for treatment of orphan cancers, as well as partnered programs with other companies who are applying our drug delivery technologies to their pipeline products.

The first of our three platforms, Midacore®, is based on Midatech’s proprietary gold nanoparticle technologies and patents. Midacore® represents a leading innovation in ‘ultra-small’ nanomedicine, enabling improved delivery of therapeutics to tumor cells and the immune system.  Midacore® can provide a carrier for conventional small molecule therapeutics as well as synthetic peptides to target cancer cell-surface proteins directly, or indirectly via T-cell mediated peptide vaccines less than 5 nanometres in diameter.  These small particles can enter cancer cells or immune processing cells to induce cell mediated immune responses specifically targeted against tumors, viral infected host cells or autoimmune disease. 

The second of these platforms is a Microsphere Sustained Release Technology Platform (Q-Sphera®), which uses micro-piezo technology to individually print drug-loaded microspheres in the size range 20-50µm.  Microsphere characteristics can be manipulated to accurately customise drug release rates.  Consistent and precise encapsulation enables drug release into the body in a highly controlled manner over a prolonged period of time, from a few weeks to more than six months.  Q-Sphera microspheres have improved injectability characteristics compared to other manufacturing methods, requiring a shorter reconstitution time and smaller needle gauge with the potential for reduced injection pain. The monodisperse nature of Q-Sphera formulations typically yields consistent and reproducible blood and local tissue drug concentrations within tight limits.  

The third drug delivery platform is Midatech’s Nano Inclusion Technology (NI), which has been applied to the formulation of insoluble and poorly brain-penetrant drugs into concentrated solutions for treatment of difficult-to-access brain tumours.  The technology is being applied to enable direct delivery of drugs to certain types of brain cancers using Convection Enhanced Delivery (CED), but it has broader general utility to improve the delivery of poorly soluble compounds.

Midatech’s pipeline of candidates in clinical and pre-clinical development offers innovative potential therapies for diseases that currently have few or no treatment options available or, in the case of MTD201, a potentially more reproducible, convenient and less painful alternative sustained-release injectable octreotide product.  Three Midatech programs have advanced into ‘first-in-human’ clinical trials.


R&D
R&D
Overview & Pipeline

Midatech’s three innovative drug delivery platforms are designed to create improved versions of existing therapies using targeted delivery, sustained release and advanced solvation technologies.  Midatech has an internal pipeline of high potential new drug products in development for treatment of orphan cancers, as well as partnered programs with other companies who are applying our drug delivery technologies to their pipeline products.

The first of our three platforms, Midacore®, is based on Midatech’s proprietary gold nanoparticle technologies and patents. Midacore® represents a leading innovation in ‘ultra-small’ nanomedicine, enabling improved delivery of therapeutics to tumor cells and the immune system.  Midacore® can provide a carrier for conventional small molecule therapeutics as well as synthetic peptides to target cancer cell-surface proteins directly, or indirectly via T-cell mediated peptide vaccines less than 5 nanometres in diameter.  These small particles can enter cancer cells or immune processing cells to induce cell mediated immune responses specifically targeted against tumors, viral infected host cells or autoimmune disease. 

The second of these platforms is a Microsphere Sustained Release Technology Platform (Q-Sphera®), which uses micro-piezo technology to individually print drug-loaded microspheres in the size range 20-50µm.  Microsphere characteristics can be manipulated to accurately customise drug release rates.  Consistent and precise encapsulation enables drug release into the body in a highly controlled manner over a prolonged period of time, from a few weeks to more than six months.  Q-Sphera microspheres have improved injectability characteristics compared to other manufacturing methods, requiring a shorter reconstitution time and smaller needle gauge with the potential for reduced injection pain. The monodisperse nature of Q-Sphera formulations typically yields consistent and reproducible blood and local tissue drug concentrations within tight limits.  

The third drug delivery platform is Midatech’s Nano Inclusion Technology (NI), which has been applied to the formulation of insoluble and poorly brain-penetrant drugs into concentrated solutions for treatment of difficult-to-access brain tumours.  The technology is being applied to enable direct delivery of drugs to certain types of brain cancers using Convection Enhanced Delivery (CED), but it has broader general utility to improve the delivery of poorly soluble compounds.

Midatech’s pipeline of candidates in clinical and pre-clinical development offers innovative potential therapies for diseases that currently have few or no treatment options available or, in the case of MTD201, a potentially more reproducible, convenient and less painful alternative sustained-release injectable octreotide product.  Three Midatech programs have advanced into ‘first-in-human’ clinical trials.


© Copyright 2018 Midatech Pharma PLC